Dual cation hydrate inhibitors

ABSTRACT

Dual cation hydrate inhibitor compositions and methods of using such compositions to, for example, inhibit the formation of gas hydrate agglomerates are provided. In some embodiments, such methods include introducing a hydrate inhibitor composition into a fluid, wherein the hydrate inhibitor composition includes at least one compound having the structural formula: 
                         
wherein each of R 1 , R 2 , and R 3  is independently a C 1  to C 6  hydrocarbon chain, wherein R 4  is selected from the group consisting of hydrogen and any C 1  to C 50  hydrocarbon chain, wherein each of R 5  and R 6  is independently selected from the group consisting of hydrogen and a C 1  to C 50  hydrocarbon chain, wherein X −  and Y −  are counter anions, and wherein each of a and b is independently an integer from 1 to 10.

CROSS-REFERENCE TO RELATED APPLICATION

The present application is a divisional application of U.S. patentapplication Ser. No. 16/753,213 filed on Apr. 2, 2020, which is a U.S.National Stage Application of International Application No.PCT/US2019/033656 filed on May 23, 2019, both of which are incorporatedherein by reference in their entireties for all purposes.

BACKGROUND

The present disclosure relates to compositions and methods useful inprocesses involving fluid flowing through, or contained in, wellborespenetrating subterranean formations, vessels, or conduits, such as pipesused, e.g., for the production and/or transport of petroleum products,natural gas, and the like.

Gas hydrates are solids that may agglomerate in a fluid that is flowingor is substantially stationary, under certain temperature and pressureconditions. For example, gas hydrates may form during hydrocarbonproduction from a subterranean formation, in particular in pipelines andother equipment during production operations. Hydrates may impede orcompletely block flow of hydrocarbons or other fluid flowing throughsuch pipelines. These blockages not only may decrease or stopproduction, potentially costing millions of dollars in lost production,but also may be very difficult and dangerous to mediate. Unless properlyhandled, gas hydrates may be volatile and/or explosive, potentiallyrupturing pipelines, damaging equipment, endangering workers, and/orcausing environmental harm.

Gas hydrates may form when water molecules become bonded together aftercoming into contact with certain “guest” gas or liquid molecules.Hydrogen bonding causes the water molecules to form a regular latticestructure, like a cage, that is stabilized by the guest gas or liquidmolecules entrapped within the lattice structure. The resultingcrystalline structure may precipitate as a solid gas hydrate. Guestmolecules can include any number of molecules such as, for example,carbon dioxide, methane, butane, propane, hydrogen, helium, freon,halogen, noble gases, and the like.

BRIEF DESCRIPTION OF THE DRAWINGS

These drawings illustrate certain aspects of some of the embodiments ofthe present disclosure and should not be used to limit or define theclaims.

FIG. 1 is a diagram illustrating a hydrate inhibitor compound inaccordance with certain embodiments of the present disclosure.

FIG. 2 is a diagram illustrating an example reaction process used toprepare a hydrate inhibitor compound in accordance with certainembodiments of the present disclosure.

FIG. 3 is a diagram illustrating an injection system used in accordancewith certain embodiments of the present disclosure.

While embodiments of this disclosure have been depicted, suchembodiments do not imply a limitation on the disclosure, and no suchlimitation should be inferred. The subject matter disclosed is capableof considerable modification, alteration, and equivalents in form andfunction, as will occur to those skilled in the pertinent art and havingthe benefit of this disclosure. The depicted and described embodimentsof this disclosure are examples only, and not exhaustive of the scope ofthe disclosure.

DESCRIPTION OF CERTAIN EMBODIMENTS

Illustrative embodiments of the present disclosure are described indetail herein. In the interest of clarity, not all features of an actualimplementation may be described in this specification. It will of coursebe appreciated that in the development of any such actual embodiment,numerous implementation-specific decisions may be made to achieve thespecific implementation goals, which may vary from one implementation toanother. Moreover, it will be appreciated that such a development effortmight be complex and time-consuming, but would nevertheless be a routineundertaking for those of ordinary skill in the art having the benefit ofthe present disclosure.

To facilitate a better understanding of the present disclosure, thefollowing examples of certain embodiments are given. In no way shouldthe following examples be read to limit, or define, the scope of theinvention. Embodiments of the present disclosure involving wellbores maybe applicable to horizontal, vertical, deviated, or otherwise nonlinearwellbores in any type of subterranean formation. Embodiments may beapplicable to injection wells, monitoring wells, and production wells,including hydrocarbon or geothermal wells.

The present disclosure relates to compositions and methods useful inprocesses involving fluid flowing through, or contained in, wellborespenetrating subterranean formations or conduits, such as pipes used,e.g., for the production and/or transport of petroleum products, naturalgas, and the like. More particularly, the present disclosure relates tocompositions and method of using such compositions to, for example,inhibit the formation of gas hydrate agglomerates.

In certain embodiments, the present disclosure may provide hydrateinhibitor compounds (e.g., LDHIs) including one or more lipophilictails, one or more hydrophilic heads, and a linking moiety. In someembodiments, the hydrate inhibitor compounds may be provided, used,and/or introduced as a salt. In certain embodiments, the presentdisclosure further provides methods of using such hydrate inhibitorcompounds to inhibit the formation of one or more hydrates in a fluid.For example, certain embodiments of the present disclosure providemethods of adding a composition including one or more hydrate inhibitorcompounds of the present disclosure to a fluid which may include any oneor more of water, a gas, a liquid hydrocarbon, and any combinationthereof. In certain embodiments, such a method may include adding to thefluid an effective amount of a hydrate inhibitor compound of the presentdisclosure to inhibit, retard, reduce, control, delay, and/or the likethe formation of hydrate agglomerates.

Among the many advantages to the compositions and methods of the presentdisclosure, only some of which are alluded to herein, the hydrateinhibitor compounds and methods of the present disclosure may, amongother benefits, provide for enhanced anti-agglomeration propertiesand/or enhanced inhibition, retardation, mitigation, reduction, control,delay, and/or the like of agglomeration of hydrates and/orhydrate-forming compounds. In certain embodiments, agglomeration ofhydrates and/or hydrate-forming compounds (and the like) may be reducedand/or inhibited to a greater degree than that achieved using otherhydrate inhibition means. In particular embodiments, compounds of thepresent disclosure may provide enhanced inhibition of agglomeration ofhydrates and/or hydrate-forming compounds.

The hydrate inhibitor compounds of the present disclosure may includetwo or more cation moieties. In some embodiments, the hydrate inhibitorcompound may include a first cation moiety including a first quaternaryammonium cation moiety. In certain embodiments, the first cation moietymay include a hydrophilic head. In certain embodiments, the hydrateinhibitor compound includes a second cation moiety including a tertiaryammonium cation or a quaternary ammonium cation. FIG. 1 illustrates thechemical structure for certain hydrate inhibitor compounds of thepresent disclosure. In certain embodiments, the cation moieties in thehydrate inhibitor compounds of the present disclosure may be bonded toother moieties of the hydrate inhibitor compound, for example, as shownwith respect to the cation moieties 105 and 106 of the hydrate inhibitorcompound 100 in FIG. 1 . In certain embodiments, the cation moieties maybe substantially of the composition —R¹R²R³N⁺— and —R⁴R⁵R⁶N⁺—. Each ofR¹, R², and R³ may independently include a C₁ to C₆ hydrocarbon chain.With further reference to FIG. 1 , R⁴ may include a hydrogen atom or aC₁ to C₅₀ hydrocarbon chain, R⁵ may include a C₁ to C₅₀ hydrocarbonchain, and R⁶ may include a C₁ to C₅₀ hydrocarbon chain. In certainembodiments, R⁶ may include a C₁ to C₆ hydrocarbon chain.

As used herein, a “hydrocarbon chain” may, unless otherwise specificallynoted, be branched, unbranched, non-cyclic, and/or cyclic; it may besubstituted or unsubstituted (that is, it may or may not contain one ormore additional moieties or functional groups in place of one or morehydrogen atoms in the hydrocarbon chain); and/or it may be saturated orunsaturated. Furthermore, as used herein, the nomenclature “C_(x) toC_(y)” refers to the number of carbon atoms in the hydrocarbon chain(here, ranging from x to y carbon atoms). As used herein,“independently” refers to the notion that the preceding items may be thesame or different.

In certain embodiments, R¹, R², and/or R³ may independently include a C₁to C₆ alkyl chain. In such embodiments wherein at least one of R¹, R²,and/or R³ includes a C₁ to C₆ hydrocarbon chain, the hydrocarbon chainmay include any one or more hydrocarbon groups selected from the groupconsisting of: alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl,alkylaryl, alkenylaryl, and any combination thereof. In suchembodiments, any one or more of R¹, R², and R³ may be branched,unbranched, non-cyclic, cyclic, saturated, and/or unsaturated. Incertain embodiments, each of R¹, R², and R³ may independently include(i) as few as any one of: 1, 2, 3, 4, 5, and 6 carbon atoms, and (ii) asmany as one of: 2, 3, 4, 5, and 6 carbon atoms. For example, suitableranges of numbers of carbon atoms in each of R¹, R², and R³ according tovarious embodiments of the present disclosure include, but are notlimited to, 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 2 to 4, 3 to 5, and4 to 6, and the like.

In some embodiments, any one or more of R¹, R², and R³ may include a C₁to C₆ alkyl chain. In some embodiments, any one or more of R¹, R², andR³ may include a C₂ to C₆ alkenyl or alkynyl chain (in which case atleast 2 carbon atoms are necessary to form an alkenyl or alkynyl chain).In some embodiments, any one or more of R¹, R², and R³ may include a C₃to C₆ cyclic moiety (in which case at least 3 carbon atoms are necessaryto form a cyclic moiety). In certain embodiments, any one or more of R¹,R², and R³ may be substituted (e.g., may include any one or morefunctional groups in addition to the hydrocarbon groups describedabove), so long as the cation moiety remains hydrophilic.

In some embodiments, R⁵ and R⁶ may independently include a C₁ to C₅₀hydrocarbon chain. In certain embodiments, R⁴ may be a hydrogen atom. Inthose embodiments, the cation moiety —R⁴R⁵R⁶N⁺— is a tertiary ammoniumcation moiety. In other embodiments, R⁴ is not a hydrogen atom. In thoseembodiments, each of R⁴, R⁵, and R⁶ may independently include a C₁ toC₅₀ hydrocarbon chain, and the cation moiety —R⁴R⁵R⁶N⁺— may be aquaternary ammonium cation moiety. In such embodiments wherein at leastone of R⁴, R⁵, and R⁶ include a C₁ to C₅₀ hydrocarbon chain, thehydrocarbon chain may include any one or more hydrocarbon groupsselected from the group consisting of: alkyl, alkenyl, alkynyl, aryl,arylalkyl, arylalkenyl, alkylaryl, alkenylaryl, and any combinationthereof. In such embodiments, any one or more of R⁴, R⁵, and R⁶ may bebranched, unbranched, non-cyclic, cyclic, saturated, and/or unsaturated.In certain embodiments, each of R⁴, R⁵, and R⁶ may independently include(i) as few as any one of: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, and 20 carbon atoms, and (ii) as many as one of: 35,36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 carbonatoms. For example, suitable ranges of numbers of carbon atoms in eachof R⁴, R⁵, and R⁶ according to various embodiments of the presentdisclosure include, but are not limited to, 1 to 50, 1 to 40, 1 to 30, 1to 20, 1 to 10, 1 to 6, 2 to 10, and 5 to 10, and the like.

In some embodiments, any one or more of R⁴, R⁵, and R⁶ may include a C₁to C₅₀ alkyl chain. In certain embodiments, any one or more of R⁴, R⁵,and R⁶ may be substituted (e.g., may include any one or more functionalgroups in addition to the hydrocarbon groups described above).

The hydrate inhibitor compounds of the present disclosure may furtherinclude one or more lipophilic tails. For example, with reference toFIG. 1 , R⁴, R⁵, and/or R⁶ of the hydrate inhibitor compound 100 mayinclude a lipophilic tail. In some embodiments, only one of R⁴, R⁵, andR⁶ is a lipophilic tail. In certain embodiments, the hydrocarbon chainof the lipophilic tail(s) may be branched or unbranched, cyclic ornon-cyclic, saturated or saturated, and/or may be any one or more ofalkyl, alkenyl, alkynyl, and aryl groups, and/or any combinationthereof. In certain embodiments, the lipophilic tail(s) may furtheroptionally be substituted with any one or more functional groups, solong as such substituted functional group(s) do not alter the lipophilicand/or hydrophobic nature of the lipophilic tail(s). In certainembodiments, each of the lipophilic tails may independently include (i)as few as any one of: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, and 20 carbon atoms, and (ii) as many as any one of: 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, 30, 35, 40, 45, and 50 carbon atoms. Forexample, suitable ranges of numbers of carbon atoms in the lipophilictail(s) according to various embodiments of the present disclosureinclude, but are not limited to 1 to 5, 3 to 5, 4 to 8, 5 to 15, 8 to18, 12 to 16, 8 to 20, 10 to 20, 15 to 20, and the like. It will beappreciated by one of ordinary skill in the art having the benefit ofthe present disclosure that even in such embodiments, additionallipophilic tails could be included in the hydrate inhibitor compound(e.g., at a point along the backbone 115 of the hydrate inhibitorcompound 100).

The hydrate inhibitor compounds of the present disclosure may furtherinclude a linking moiety. As used herein, “linking moiety” refers to anyportion of the hydrate inhibitor compound that provides spacing betweenthe cation moieties and/or the lipophilic tail(s). In certainembodiments, one or more lipophilic tails may be connected to the cationmoieties via the linking moiety. In some embodiments, two or more cationmoieties may be connected to the each other via a linking moiety. Forexample, in the hydrate inhibitor compound 100 shown in FIG. 1 , firstcation moiety 105 is connected to second cation moiety 106 via linkingmoiety 110.

In certain embodiments, the linking moiety may each include one or morehydrocarbon chains of any length, branched or unbranched, and/orsaturated or unsaturated (so long as the overall hydrate inhibitorcompound maintains amphiphilic character). Hydrocarbon chain lengthsinclude C₁ to C₅₀ chains or longer. In certain embodiments, the linkingmoiety may be any one or more of methyl, ethyl, propyl, butyl, pentyl,hexyl, heptyl, octyl, nonyl, decyl, etc. In certain embodiments, thelinking moiety may be substituted such that it includes any kind and anynumber of functional groups (so long as the hydrate inhibitor compoundmaintains both hydrophobic and hydrophilic portions). In suchembodiments, the one or more functional groups that may be included onthe linking moiety according to some embodiments should not adverselyaffect the hydrophilic nature of a hydrophilic head, nor should theyadversely affect the lipophilic nature of the lipophilic tail(s).Examples of suitable functional groups that may be included in thelinking moiety, the lipophilic tail(s), and/or the R-groups (R¹, R², R³,R⁴, R⁵, R⁶) of the present disclosure may include any one or more of: anester, ether, amine, sulfonamide, amide, ketone, carbonyl, isocyanate,urea, urethane, and any combination thereof. In some embodiments, theone or more functional groups on the linking moiety may include anygroup capable of reacting with an amine, provided that functionalgroup's inclusion in the linking moiety allows the hydrate inhibitorcompound to maintain its amphiphilic character.

For example, the hydrate inhibitor compound 100 of FIG. 1 includesexample linking moiety 110 including an amide group as well as two alkylchains of the general formulas C_(a)H_(2a) and C_(b)H_(2b) on eitherside of the amide group. In certain embodiments, each of a and b mayindependently be an integer from 1 to 10. In certain embodiments, eachalkyl chain in the linking moiety may include (i) as few as any one of:1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 carbon atoms, and (ii) as many as anyone of: 2, 3, 4, 5, 6, 7, 8, 9, and 10 carbon atoms.

The hydrate inhibitor compounds of the present disclosure may instead orin addition be characterized as reaction products. For instance, in someembodiments, the present disclosure provides hydrate inhibitor compoundsthat may be characterized as reaction products of: (1) adialkylaminoalkylamine having the general formula H₂N—(CH₂)_(c)—NR¹R²and (2) a first intermediate formed as the reaction product of one ormore unsaturated carboxylic acids or esters containing an alkene chain(e.g., acrylates) and an amine. In some embodiments, the “dialkyl”groups of the dialkylaminoalkylamine may be either the same ordifferent, and the R¹ and R² groups may depend upon, among otherfactors, the identity of the dialkyl groups of thedialkylaminoalkylamine. In certain embodiments, the length of the“alkyl” chain (i.e., (CH₂)_(c)) of the dialkylaminoalkylamine may varyfrom (CH₂)₁ to (CH₂)₁₀, and the length of an alkyl chain in the linkingmoiety having the general formula C_(b)H_(2b) may depend upon, amongother factors, the length of the alkyl chain of thedialkylaminoalkylamine. In certain embodiments, the unsaturatedcarboxylic acids or esters containing an alkene chain may be an alkylalkenoate (e.g., an alkyl methacrylate, an alkyl acrylate (for example,methyl acrylate)), an alkenoic acid (e.g., acrylic acid), and anycombination thereof. In certain embodiments, the length of an alkylchain in the linking moiety having the general formula C_(a)H_(2a) maydepend upon, among other factors, the identity of the unsaturatedcarboxylic acid or ester.

In certain embodiments, the amine may have one or more hydrocarbonchains each of a length from C₁ to C₅₀, and the lipophilic tails R⁴ andR⁵ of the hydrate inhibitor compound may depend upon, among otherfactors, the identity of the hydrocarbon chains. In certain embodiments,the amine may include one or more functional groups and a portion of thefunctional group may be included in the lipophilic tails R⁴ and R⁵ ofthe hydrate inhibitor compound. In some embodiments, R⁴ and R⁵ includeC₁ to C₅₀ hydrocarbon chains resulting from a reaction between anacrylate or a methacrylate and an amine. Suitable amines for reactionmay include, but are not limited to, any primary or secondary fattyamine derived from one or more fatty acids selected from the groupconsisting of: corn oil, canola oil, coconut oil, safflower oil, sesameoil, palm oil, cottonseed oil, soybean oil, olive oil, sunflower oil,hemp oil, wheat germ oil, palm kernel oil, vegetable oil, tall oil,tallow oil, caprylic acid, capric acid, lauric acid, stearic acid,myristic acid, myristoleic acid, palmitic acid, palmitoleic acid,stearic acid, sapienic acid, elaidic acid, vaccenic acid, linoleic acid,arachidic acid, arachidonic acid, eicosapentaenoic acid, erucic acid,docosahexaenoic acid, behenic acid, lignoceric acid, cerotic acid, oleicacids (cis- and trans-), and any combination thereof. Suitable aminesfor reaction also may include, but are not limited to, any syntheticprimary or secondary amine including, but not limited to, butylamine,pentylamine, hexylamine, octylamine, dodecylamine, N-methyldodecylamine,N-methyloctylamine, didodecylamine, and the like, and any combinationthereof.

In some embodiments, the reaction product of (1) thedialkylaminoalkylamine and (2) the first intermediate may form a secondintermediate that may further be reacted with (3) one or more alkylatingagents. In such embodiments, R³ and/or R⁶ of the cation moieties maydepend upon, among other factors, the alkyl group of the alkylatingagent(s). In certain embodiments, the one or more alkylating agents maybe a carbonate, a halide, a sulfate, an organic sulfonate, a phosphate,a phosphonate, a hydroxide, and/or any combination thereof. In someembodiments, the alkylating agent may include a diethyl sulfate. Incertain embodiments, the hydrate inhibitor compound is a reactionproduct of a reaction between (i) an alkylating agent and (ii) a secondintermediate resulting from a reaction between a dialkylaminoalkylamineand a first intermediate, the first intermediate resulting from areaction between an acrylate or a methacrylate and an amine.

FIG. 2 illustrates a potential reaction scheme for forming a hydrateinhibitor compound in accordance with certain embodiments of the presentdisclosure. In the reaction scheme shown, acrylic acid 201 reacts withamine 202 (which, as shown in FIG. 2 , includes hydrocarbon chains R⁴and R⁵) to produce first intermediate 203. The first intermediate 203 inturn reacts with dialkylaminopropylamine 204 (which, as shown in FIG. 2, includes hydrocarbon chains R¹ and R²) forming a second intermediate205. The second intermediate 205 in turn reacts with one or morealkylating agents 206 and 207 (which, as shown in FIG. 2 , includehydrocarbon chains R³ and R⁶) to form hydrate inhibitor compound 100. Ascan be seen, hydrate inhibitor compound 100 includes two cation moieties105 and 106 including R-groups R¹ and R² (retaining the hydrocarbonstructure R¹ and R² of dialkylaminopropylamine 204), R-group R³(retaining the hydrocarbon structure R³ of alkylating agent 206), R⁴ andR⁵ (retaining the hydrocarbon structures R⁴ and R⁵ of amine 202) and R⁶(retaining the hydrocarbon structure R⁶ of alkylating agent 207) and alinking moiety including an amide group with an alkyl chain on each sideof the amide group and an amino group connected to R⁴ and R⁵. Thealkylating agents 206 and 207 may be the same or different. Suchreactions may in some embodiments take place at about 80° C. to about250° C. at approximately atmospheric pressure or lower pressure. It willbe appreciated by one of ordinary skill in the art having the benefit ofthe present disclosure that various modifications may be made to thisreaction scheme to produce other embodiments.

In certain embodiments, the hydrate inhibitor compounds of the presentdisclosure may be provided, used, and/or introduced as a salt of one ormore of the compounds described herein. In such embodiments, the saltmay include one or more counter anions. For example, the hydrateinhibitor compound 100 as shown in FIGS. 1 and 2 includes a salt withcounter anions X⁻ and Y⁻. In certain embodiments, such salts may whollyor partially dissociate in aqueous solution. In other embodiments, thesalts may remain substantially associated (either with the originalanion or with other ions from solution). The suitable counter anions mayinclude, for example, a carboxylate, a halide, a sulfate, an organicsulfonate, a hydroxide, and/or any combination thereof. It will beappreciated by one of ordinary skill in the art having the benefit ofthis disclosure that salts may be formed with other counter anionsinstead of or in addition to the counter anions specifically disclosedherein.

In certain embodiments, the hydrate inhibitor compounds of the presentdisclosure may have substantially the following structural formula:

In such embodiments, each of R¹, R², and R³ may independently include aC₁ to C₆ hydrocarbon chain; R⁴ may include a hydrogen atom or a C₁ toC₅₀ hydrocarbon chain; R⁵ and R⁶ are each independently selected fromthe group consisting of hydrogen and a C₁ to C₅₀ hydrocarbon chain; Xand Y may independently be counter anions according to the previousdiscussion; and each of a and b may be independently an integer from 1to 10 according to the previous discussion of the alkyl chains of thelinking moiety.

As previously noted, the present disclosure in some embodiments furtherprovides methods of using the hydrate inhibitor compounds of the presentdisclosure. In certain embodiments, the hydrate inhibitor compounds ofthe present disclosure may be used to inhibit, retard, mitigate, reduce,control, and/or delay the formation of one or more hydrates oragglomerates of hydrates. For example, the hydrate inhibitor compoundsof the present disclosure may be used to reduced and/or prevent hydrateparticles from agglomerating by, for example, ensuring the hydrateparticles remain small in size, well-dispersed in a fluid, and/ornon-adherent to other hydrate particles and surfaces the hydrateparticles may contact (e.g., conduit wall). Without limiting the presentdisclosure to a particular theory, it is believed that the hydrateinhibitor compounds of the present disclosure may attach to the surfaceof hydrate particles and that the lipophilic tail of the hydrateinhibitor compounds may reduce and/or prevent agglomeration and/oraggregation of the hydrate particles and/or may help to disperse thehydrate particles in a fluid.

In certain embodiments, one or more hydrate inhibitor compounds of thepresent disclosure may be introduced into a fluid including any one ormore of water, a gas, a liquid hydrocarbon, and any combination thereof.Although listed separately from liquid hydrocarbon, the gas may in someembodiments include gaseous hydrocarbon, though the gas need notnecessarily include hydrocarbon. In some embodiments, the gas mayinclude, but is not limited to O₂, H₂, N₂, CO₂, CH₄, H₂S, Ar, Kr, Xe, ahydrocarbon, a freon, and any combination thereof. In certainembodiments, the hydrate inhibitor compound may be introduced into thefluid through a conduit or an injection point. In certain embodiments,one or more hydrate inhibitor compounds of the present disclosure may beintroduced into a wellhead, a wellbore, a subterranean formation, aconduit, a vessel, and the like and may contact and/or be introducedinto a fluid residing therein.

In certain embodiments, the fluid may be flowing or it may besubstantially stationary. In some instances, the fluid may be in ahigh-pressure, low-temperature environment such that hydrates form inthe fluid. In certain embodiments, hydrates may form in the fluid whenthe pressure of the environment in which the fluid flows or resides isin the range from about 14.7 psi to about 20,000 psi. In certainembodiments, hydrates may form in the fluid when the temperature of theenvironment in which the fluid flows or resides is in the range fromabout 0° C. (32° F.) to about 30° C. (86° F.). In certain embodiments,the formation of hydrates in a fluid may depend on both the pressure andthe temperature of the fluid and/or the environment in which the fluidis located. For example, at lower temperatures (e.g., below about 5° C.(41° F.)), methane hydrates may form over a wide range of pressures(e.g., above about 400 psi). Conversely, at higher pressures (e.g.,above about 1400 psi), methane hydrates may form over a wide range oftemperatures (e.g., up to about 15° C. (59° F.)).

In certain embodiments, the fluid may be within a vessel, or within aconduit (e.g., a conduit that may transport the fluid), or within asubterranean formation, or within a wellbore penetrating a portion ofthe subterranean formation, and/or within a wellhead of a wellbore.Examples of conduits include, but are not limited to, pipelines,production piping, subsea tubulars, process equipment, and the like asused in industrial settings and/or as used in the production of oiland/or gas from a subterranean formation, and the like. The conduit mayin certain embodiments penetrate at least a portion of a subterraneanformation, as in the case of an oil and/or gas well. In particularembodiments, the conduit may be a wellhead, a wellbore, or may belocated within a wellbore penetrating at least a portion of asubterranean formation. Such oil and/or gas well may, for example, be asubsea well (e.g., with the subterranean formation being located belowthe sea floor), or it may be a surface well (e.g., with the subterraneanformation being located belowground). A vessel or conduit according toother embodiments may be located in an industrial setting such as arefinery (e.g., separation vessels, dehydration units, pipelines, heatexchangers, and the like), or it may be a transportation pipeline.

In some embodiments, the hydrate inhibitor compounds of the presentdisclosure initially may be incorporated into a composition prior tobeing introduced into the fluid. The composition may be any suitablecomposition in which the hydrate inhibitor compound may be included. Forexample, in some embodiments, the composition may be a treatment fluidfor use in a wellbore penetrating a subterranean formation during, forinstance, oil and/or gas recovery operations. The composition mayinclude a solvent for the hydrate inhibitor compound. Suitable solventsinclude, for example, any alcohol, methanol, ethanol, isopropyl alcohol,glycol, glycol ethers, any organic solvent, toluene, xylene, monobutylether, hexane, cyclohexane, and/or any combination thereof.

In certain embodiments, one or more hydrate inhibitor compounds of thepresent disclosure may be introduced into and/or contact the fluid in anamount from about 0.1% to about 10% by volume based on the volume ofwater in the fluid (or in other words, about 0.1% to about 10% by volumebased on water cut). In various embodiments, the hydrate inhibitorcompounds of the present disclosure may be used as low dosage hydrateinhibitors (LDHIs) such that an effective amount of one or more hydrateinhibitor compounds for inhibiting, retarding, mitigating, reducing,controlling, delaying, and/or the like agglomeration of hydrates may beas low as any of: 0.1, 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00,2.25, and 2.50% by volume based on water cut. An effective amount may beas high as any of: 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0,5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, and 10.0% by volume basedon water cut. Thus, in some embodiments, an effective amount of hydrateinhibitor compounds of the present disclosure for inhibiting, retarding,mitigating, reducing, controlling, delaying, and/or the likeagglomeration of hydrates may be about 0.1% to about 5.5% by volumebased on water cut of the fluid; in other embodiments, about 0.1% toabout 3.0% by volume based on water cut of the fluid; in otherembodiments, about 0.25% to about 2.5% by volume based on water cut ofthe fluid; and in other embodiments, about 0.5% to about 2.0% by volumebased on water cut of the fluid.

In certain embodiments, one or more hydrate inhibitor compounds of thepresent disclosure may be introduced to and/or contact any of variousfluids having different water cuts (i.e., the ratio of the volume ofwater in the fluid to the total volume of the fluid). For example, insome embodiments the water cut of the fluid may be about 1 to about 65%.In other embodiments, the water cut may be as low as any one of: 20, 25,30, 35, 40, 45, 50, 55, 60, and 65%; while the water cut may be as highas any one of: 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, and 95%.In certain embodiments, a fluid may have a water cut of 30% or more, 35%or more, 40% or more, 45% or more, 50% or more, 55% or more, or 60% ormore, up to about 99%. In yet other embodiments, one or more hydrateinhibitor compounds of the present disclosure may be introduced into orcontact a fluid with any water cut ranging from about 1% to about 99%.

In certain embodiments, the fluid to which one or more hydrate inhibitorcompounds of the present disclosure may be introduced optionally mayinclude any number of additives. Examples of such additives include, butare not limited to, salts, surfactants, acids, proppant particulates,diverting agents, fluid loss control additives, nitrogen, carbondioxide, surface modifying agents, tackifying agents, foamers, corrosioninhibitors, scale inhibitors, other hydrate inhibitors, catalysts, claycontrol agents, biocides, friction reducers, antifoam agents, bridgingagents, flocculants, H₂S scavengers, CO₂ scavengers, oxygen scavengers,lubricants, viscosifiers, breakers, weighting agents, relativepermeability modifiers, resins, wetting agents, coating enhancementagents, filter cake removal agents, antifreeze agents (e.g., glycols),and the like. A person skilled in the art, with the benefit of thisdisclosure, will recognize the types of additives that may be includedin the fluids of the present disclosure for a particular application. Itfurther will be appreciated by one of ordinary skill in the art havingthe benefit of the present disclosure that the amount of the hydrateinhibitor compounds of the present disclosure effective for inhibiting,retarding, reducing, controlling, delaying, and/or the like hydrates maydepend upon, for example, the volume of water in the fluid and/oradditives in the fluid.

In certain embodiments, the hydrate inhibitor compounds of the presentdisclosure may be introduced into a wellhead of a wellbore penetratingat least a portion of the subterranean formation, a wellbore, asubterranean formation, a vessel, and/or a conduit (and/or into a fluidwithin any of the foregoing) using any method or equipment known in theart. For example, the hydrate inhibitor compounds of the presentdisclosure may be applied to a subterranean formation and/or wellboreusing batch treatments, squeeze treatments, continuous treatments,and/or any combination thereof. In certain embodiments, a batchtreatment may be performed in a subterranean formation by stoppingproduction from the well and pumping the dissolved hydrate inhibitorsinto a wellbore, which may be performed at one or more points in timeduring the life of a well. In other embodiments, a squeeze treatment maybe performed by dissolving a hydrate inhibitor compound of the presentdisclosure in a suitable solvent at a suitable concentration andsqueezing that solvent carrying the hydrate inhibitor downhole into theformation, allowing production out of the formation to bring the hydrateinhibitor to its desired location. In other embodiments, a hydrateinhibitor compound of the present disclosure may be injected into aportion of a subterranean formation using an annular space or capillaryinjection system to continuously introduce the hydrate inhibitorcompound into the formation. In certain embodiments, a composition (suchas a treatment fluid) including a hydrate inhibitor compound of thepresent disclosure may be circulated in the wellbore using the sametypes of pumping systems and equipment at the surface that are used tointroduce treatment fluids or additives into a wellbore penetrating atleast a portion of the subterranean formation.

In certain embodiments, the methods of the present disclosure includeapplying the hydrate inhibitor compound to a fluid. In some embodiments,the method of applying the hydrate inhibitor compound to prevent hydrateplugging includes introducing the hydrate inhibitor compound into anumbilical line or a capillary line in which a fluid is located.

In certain embodiments, the fluids or additives may be formed at a wellsite where the operation or treatment is conducted, either by batchmixing or continuous (“on-the-fly”) mixing. The term “on-the-fly” isused herein to include methods of combining two or more componentswherein a flowing stream of one element is continuously introduced intoa flowing stream of at least one other component so that the streams arecombined and mixed while continuing to flow as a single stream as partof the on-going treatment. Such mixing can also be described as“real-time” mixing. In other embodiments, the treatment fluids of thepresent disclosure may be prepared, either in whole or in part, at anoffsite location and transported to the site where the treatment oroperation is conducted. In introducing a composition of the presentdisclosure into a vessel, conduit (e.g., an umbilical, capillary, ortubing), wellbore, and/or portion of a subterranean formation,components of the composition may be mixed together prior tointroduction into a vessel, conduit, wellbore, and/or formationtogether, or one or more components may be introduced into the vessel,conduit, wellbore, and/or formation at the surface separately from othercomponents such that the components mix or intermingle in a portion ofthe vessel, conduit, wellbore, and/or formation to form a composition.In either such case, the composition is deemed to be introduced into atleast a portion of the vessel, conduit, wellbore, and/or subterraneanformation for purposes of the present disclosure.

For example, a hydrate inhibitor compound of the present disclosure maybe introduced into a wellbore and/or tubing using a capillary injectionsystem as shown in FIG. 3 . Referring now to FIG. 3 , wellbore 305 hasbeen drilled to penetrate a portion of a subterranean formation 300. Atubing 310 (e.g., production tubing) has been placed in the wellbore305. A capillary injection tube 330 is disposed in the annular spacebetween the outer surface of tubing 310 and the inner wall of wellbore305. The capillary injection tube 330 is connected to a side-pocketmandrel 340 at a lower section of the tubing 310. A hydrate inhibitorcompound of the present disclosure may be injected into capillaryinjection tube 330 at the wellhead 308 at the surface such that it mixeswith production fluid at or near the side-pocket mandrel 340. As theproduction fluid flows through the tubing 310, the hydrate inhibitorcompound may prevent, inhibit, retard, reduce, control, and/or delay theformation of one or more hydrates within the tubing 310. Other capillaryinjection systems and side pocket mandrel devices (e.g., those used ingas lift production) may be used in a similar manner to the system shownin FIG. 3 .

In certain embodiments, a hydrate inhibitor compound of the presentdisclosure may be added to a conduit such as a pipeline where one ormore fluids enter the conduit and/or at one or more other locationsalong the length of the conduit. In such embodiments, the hydrateinhibitor compound may be added in batches or injected substantiallycontinuously while the pipeline is being used, for example, to maintainthe concentration of the hydrate inhibitor compound of the presentdisclosure in the fluid at a certain amount (e.g., one or more of theconcentrations referenced above).

Once introduced into a fluid, subterranean formation, wellbore,pipeline, vessel, or other location, the hydrate inhibitor compound mayinhibit, retard, reduce, control, and/or delay the formation of one ormore hydrates or the agglomeration of hydrate crystals within the fluid,subterranean formation, wellbore, pipeline, vessel, or other location.

To facilitate a better understanding of the present disclosure, thefollowing examples of certain aspects of certain embodiments are given.The following examples are not the only examples that could be givenaccording to the present disclosure and are not intended to limit thescope of the disclosure or claims.

EXAMPLE

Rocking cell tests were carried out on several samples includingdifferent hydrate inhibitor compounds having structures according tosome embodiments of the present disclosure. Rocking cell tests involvedthe injection of oil, water, a hydrate inhibitor compound, and gas intoa cell at representative conditions. Gas was injected into the cell toachieve a desired working pressure during the experiment. Each cell wasof a fixed volume and contained constant mass during the experiment;that is, oil, water, a hydrate inhibitor compound, and gas were injectedat the beginning of the experiment, but thereafter the cell was closedto mass transfer in or out of the cell. Each cell also included amagnetic ball in the space where fluids are injected. The ball aided inagitation of the fluids during rocking. In addition, magnetic sensors onboth ends of the cell detected whether the magnetic ball's movementsthrough the fluids were hindered during rocking, wherein such hindrancecould indicate the presence of hydrates. The cell also permitted visualobservation of its contents during the experiment.

Initially, amounts of Mission Condensate oil, 6% NaCl, and a hydrateinhibitor compound were injected into the cell so as to achieve a watercut of 55% (i.e., fraction of aqueous phase by volume in the totalfluid) and a hydrate inhibitor compound dosage of 0.25 to 5% by volumeof the water phase (i.e., volume % of hydrate inhibitor compound onwater cut basis). After injection of oil, brine, and hydrate inhibitorcompound, gas was injected to reach a desired pressure (e.g., workingpressure of a conduit of interest for evaluation of the hydrateinhibitor compound, in this case around 2,800 psi).

Following injection of the gas, the cell was closed and rocked forapproximately 2 hours to emulsify the fluids therein. The temperaturewas then ramped down from about 20° C. to about 4° C. over a period ofabout 1 hour, and rocking was continued for around 16 hours after thetemperature reached about 4° C. The rocking was then stopped for aperiod of time while the cell is horizontal (e.g., to simulate a systemshut-in). This “shut-in” period lasts for at least 6 hours, varying onlyso that the restart of rocking could be visually observed.

Visual inspection of the contents of the cell was made throughout thetests for visual rating of the performance of the hydrate inhibitorcompound as a hydrate inhibitor. Samples were prepared of compositionsincluding hydrate inhibitor compounds with structures according to someembodiments of the present disclosure. The samples prepared includedhydrate inhibitor compounds having the following structure:

The samples having the above structure passed the rocking cell test inthe fluid with a water cut of 55%. These results of the rocking celltests indicated that the compositions and methods of the presentdisclosure may facilitate, among other benefits, the inhibition,retardation, reduction, control, and/or delay of agglomeration ofhydrates and/or hydrate-forming compounds in fluids having a water cutsas high as 55%.

An embodiment of the present disclosure is a method including:introducing a hydrate inhibitor composition into a fluid, wherein thehydrate inhibitor composition includes at least one compound having thestructural formula:

wherein each of R¹, R², and R³ is independently a C₁ to C₆ hydrocarbonchain, wherein R⁴ is selected from the group consisting of hydrogen andany C₁ to C₅₀ hydrocarbon chain, wherein each of R⁵ and R⁶ isindependently selected from the group consisting of hydrogen and a C₁ toC₅₀ hydrocarbon chain, wherein X⁻ and Y⁻ are counter anions, and whereineach of a and b is independently an integer from 1 to 10.

In one or more embodiments described above, X⁻ and Y⁻ are selected fromthe group consisting of: a carboxylate, a halide, a sulfate, an organicsulfonate, a phosphate, a phosphonate, a hydroxide, and any combinationthereof. In one or more embodiments described above, the fluid includesat least one component selected from the group consisting of: water, agas, a liquid hydrocarbon, and any combination thereof. In one or moreembodiments described above, the hydrate inhibitor composition isintroduced into the fluid through a conduit or an injection point influid communication with a wellbore in which the fluid resides. In oneor more embodiments described above, the hydrate inhibitor compositionis introduced into a wellbore penetrating at least a portion of asubterranean formation through which the fluid is flowing. In one ormore embodiments described above, the fluid includes water and has awater cut of up to 80%. In one or more embodiments described above, thehydrate inhibitor composition is introduced into the fluid through anumbilical or a capillary line. In one or more embodiments describedabove, the fluid includes water and the hydrate inhibitor composition isintroduced into the fluid in an amount such that the compound is presentin the fluid in an amount from about 0.1% to about 10% by volume basedon the water cut of the fluid. In one or more embodiments describedabove, each of R⁴ and R⁵ is a C₁ to C₅₀ hydrocarbon chain resulting froma reaction between an acrylate or a methacrylate and an amine, the aminebeing selected from the group consisting of: a synthetic primary orsecondary amine selected from the group consisting of: butylamine,pentylamine, hexylamine, octylamine, dodecylamine, N-methyldodecylamine,N-methyloctylamine, didodecylamine, and any combination thereof; aprimary or secondary fatty amine derived from one or more fatty acidsselected from the group consisting of: corn oil, canola oil, coconutoil, safflower oil, sesame oil, palm oil, cottonseed oil, soybean oil,olive oil, sunflower oil, hemp oil, wheat germ oil, tall oil, palmkernel oil, vegetable oil, tallow oil, caprylic acid, capric acid,lauric acid, stearic acid, myristic acid, myristoleic acid, palmiticacid, palmitoleic acid, stearic acid, sapienic acid, elaidic acid,vaccenic acid, linoleic acid, arachidic acid, arachidonic acid,eicosapentaenoic acid, erucic acid, docosahexaenoic acid, behenic acid,lignoceric acid, cerotic acid, oleic acids (cis- and trans-), and anycombination thereof, and any combination thereof. In one or moreembodiments described above, the at least one compound is a reactionproduct of a reaction between (i) an alkylating agent and (ii) a secondintermediate resulting from a reaction between a dialkylaminoalkylamineand a first intermediate, the first intermediate resulting from areaction between an acrylate or a methacrylate and an amine. In one ormore embodiments described above, the fluid resides in a wellborepenetrating at least a portion of a subterranean formation.

In another embodiment, the present disclosure provides a methodincluding introducing a hydrate inhibitor composition into a conduitthrough which a fluid is flowing, wherein the hydrate inhibitorcomposition includes at least one compound having the structuralformula:

wherein each of R¹, R², and R³ is independently a C₁ to C₆ hydrocarbonchain, wherein R⁴ is selected from the group consisting of hydrogen andany C₁ to C₅₀ hydrocarbon chain, wherein each of R⁵ and R⁶ isindependently selected from the group consisting of hydrogen and a C₁ toC₅₀ hydrocarbon chain, wherein X⁻ and Y⁻ are counter anions, and whereineach of a and b is independently an integer from 1 to 10.

In one or more embodiments described above, X⁻ and Y⁻ are selected fromthe group consisting of: a carboxylate, a halide, a sulfate, an organicsulfonate, a phosphate, a phosphonate, a hydroxide, and any combinationthereof. In one or more embodiments described above, the fluid includesat least one component selected from the group consisting of: water, agas, a liquid hydrocarbon, and any combination thereof. In one or moreembodiments described above, the fluid includes water and has a watercut of up 80%. In one or more embodiments described above, each of R⁴and R⁵ is a C₁ to C₅₀ hydrocarbon chain resulting from a reactionbetween an acrylate or a methacrylate and an amine, the amine beingselected from the group consisting of: a synthetic primary or secondaryamine selected from the group consisting of: butylamine, pentylamine,hexylamine, octylamine, dodecylamine, N-methyldodecylamine,N-methyloctylamine, didodecylamine, and any combination thereof; aprimary or secondary fatty amine derived from one or more fatty acidsselected from the group consisting of: corn oil, canola oil, coconutoil, safflower oil, sesame oil, palm oil, cottonseed oil, soybean oil,olive oil, sunflower oil, hemp oil, wheat germ oil, tall oil, palmkernel oil, vegetable oil, tallow oil, caprylic acid, capric acid,lauric acid, stearic acid, myristic acid, myristoleic acid, palmiticacid, palmitoleic acid, stearic acid, sapienic acid, elaidic acid,vaccenic acid, linoleic acid, arachidic acid, arachidonic acid,eicosapentaenoic acid, erucic acid, docosahexaenoic acid, behenic acid,lignoceric acid, cerotic acid, oleic acids (cis- and trans-), and anycombination thereof; and any combination thereof.

In another embodiment, the present disclosure provides a compositionincluding compound having the structural formula:

wherein each of R¹, R², and R³ is independently a C₁ to C₆ hydrocarbonchain, wherein R⁴ is selected from the group consisting of hydrogen andany C₁ to C₅₀ hydrocarbon chain, wherein each of R⁵ and R⁶ isindependently selected from the group consisting of hydrogen and a C₁ toC₅₀ hydrocarbon chain, herein X⁻ and Y⁻ are counter anions, and whereineach of a and b is independently an integer from 1 to 10.

In one or more embodiments described above, X⁻ and Y⁻ are selected fromthe group consisting of: a carboxylate, a halide, a sulfate, an organicsulfonate, a phosphate, a phosphonate, a hydroxide, and any combinationthereof. In one or more embodiments described above, each of R⁴ and R⁵is a C₁ to C₅₀ hydrocarbon chain resulting from a reaction between anacrylate or a methacrylate and an amine, the amine being selected fromthe group consisting of: a synthetic primary or secondary amine selectedfrom the group consisting of: butylamine, pentylamine, hexylamine,octylamine, dodecylamine, N-methyldodecylamine, N-methyloctylamine,didodecylamine, and any combination thereof; a primary or secondaryfatty amine derived from one or more fatty acids selected from the groupconsisting of: corn oil, canola oil, coconut oil, safflower oil, sesameoil, palm oil, cottonseed oil, soybean oil, olive oil, sunflower oil,hemp oil, wheat germ oil, tall oil, palm kernel oil, vegetable oil,tallow oil, caprylic acid, capric acid, lauric acid, stearic acid,myristic acid, myristoleic acid, palmitic acid, palmitoleic acid,stearic acid, sapienic acid, elaidic acid, vaccenic acid, linoleic acid,arachidic acid, arachidonic acid, eicosapentaenoic acid, erucic acid,docosahexaenoic acid, behenic acid, lignoceric acid, cerotic acid, oleicacids (cis- and trans-), and any combination thereof; and anycombination thereof. In one or more embodiments described above, thecomposition further includes a solvent selected from the groupconsisting of: an alcohol, methanol, ethanol, isopropyl alcohol, glycol,glycol ethers, an organic solvent, toluene, xylene, monobutyl ether,hexane, cyclohexane, and any combination thereof.

Therefore, the present disclosure is well adapted to attain the ends andadvantages mentioned as well as those that are inherent therein. Theparticular embodiments disclosed above are illustrative only, as thepresent disclosure may be modified and practiced in different butequivalent manners apparent to those skilled in the art having thebenefit of the teachings herein. While numerous changes may be made bythose skilled in the art, such changes are encompassed within the spiritof the subject matter defined by the appended claims. Furthermore, nolimitations are intended to the details of construction or design hereinshown, other than as described in the claims below. It is thereforeevident that the particular illustrative embodiments disclosed above maybe altered or modified and all such variations are considered within thescope and spirit of the present disclosure. In particular, every rangeof values (e.g., “from about a to about b,” or, equivalently, “fromapproximately a to b,” or, equivalently, “from approximately a-b”)disclosed herein is to be understood as referring to the power set (theset of all subsets) of the respective range of values. The terms in theclaims have their plain, ordinary meaning unless otherwise explicitlyand clearly defined by the patentee.

What is claimed is:
 1. A hydrate inhibitor composition comprising atleast one compound of the structural formula:

wherein each of R¹, R², and R³ is independently a C₁ to C₆ hydrocarbonchain, wherein each of R⁴ and R⁵ is independently selected from thegroup consisting of hydrogen and any C₁ to C₅₀ hydrocarbon chainresulting from a reaction between an acrylate or a methacrylate and anamine, wherein R⁶ is selected from the group consisting of hydrogen anda C₁ to C₅₀ hydrocarbon chain, wherein X⁻ and Y⁻ are counter anions, andwherein each of a and b is independently an integer from 1 to
 10. 2. Thehydrate inhibitor composition of claim 1 wherein X⁻ and Y⁻ are selectedfrom the group consisting of: a carboxylate, a halide, a sulfate, anorganic sulfonate, a phosphate, a phosphonate, a hydroxide, and anycombination thereof.
 3. The hydrate inhibitor composition of claim 1,wherein the amine is selected from the group consisting of: a syntheticprimary or secondary amine selected from the group consisting of:butylamine, amine, hexylamine, octylamine, dodecylamine,N-methyldodecylamine, N-methyloctylamine, didodecylamine, and anycombination thereof; a primary or secondary fatty amine derived from oneor more fatty acids selected from the group consisting of: corn oil,canola oil, coconut oil, safflower oil, sesame oil, palm oil, cottonseedoil, soybean oil, olive oil, sunflower oil, hemp oil, wheat germ oil,palm kernel oil, vegetable oil, tall oil, tallow oil, caprylic acid,capric acid, lauric acid, stearic acid, myristic acid, myristoleic acid,palmitic acid, palmitoleic acid, stearic acid, sapienic acid, elaidicacid, vaccenic acid, linoleic acid, arachidic acid, arachidonic acid,eicosapentaenoic acid, erucic acid, docosahexaenoic acid, behenic acid,lignoceric acid, cerotic acid, oleic acids (cis- and trans-), and anycombination thereof; and any combination thereof.
 4. The hydrateinhibitor composition of claim 1 further comprising a solvent selectedfrom the group consisting of: an alcohol, methanol, ethanol, isopropylalcohol, glycol, glycol ethers, an organic solvent, toluene, xylene,monobutyl ether, hexane, cyclohexane, and any combination thereof. 5.The hydrate inhibitor composition of claim 1 wherein the at least onecompound is a reaction product of a reaction between (i) an alkylatingagent and (ii) a second intermediate resulting from a reaction between adialkylaminoalkylamine and a first intermediate, the first intermediateresulting from a reaction between an acrylate or a methacrylate and anamine.
 6. A treatment fluid for use in a wellbore, the treatment fluidcomprising a liquid component and a hydrate inhibitor that comprises atleast one compound of the structural formula:

wherein each of R¹, R², and R³ is independently a C₁ to C₆ hydrocarbonchain, wherein each of R⁴ and R⁵ is independently selected from thegroup consisting of hydrogen and any C₁ to C₅₀ hydrocarbon chainresulting from a reaction between an acrylate or a methacrylate and anamine, wherein R⁶ is selected from the group consisting of hydrogen anda C₁ to C₅₀ hydrocarbon chain, wherein X⁻ and Y⁻ are counter anions, andwherein each of a and b is independently an integer from 1 to
 10. 7. Thetreatment fluid of claim 6 wherein the liquid component comprises atleast one component selected from the group consisting of: water, a gas,a liquid hydrocarbon, and any combination thereof.
 8. The treatmentfluid of claim 6 wherein the treatment fluid comprises water and has awater cut of up to 80%.
 9. The treatment fluid of claim 6 wherein thetreatment fluid comprises water and the hydrate inhibitor composition ispresent in the treatment fluid in an amount such that the compound ispresent in the fluid in an amount from about 0.1% to about 10% by volumebased on a water cut of the fluid.
 10. The treatment fluid of claim 9,wherein the amine is selected from the group consisting of: a syntheticprimary or secondary amine selected from the group consisting of:butylamine, amine, hexylamine, octylamine, dodecylamine,N-methyldodecylamine, N-methyloctylamine, didodecylamine, and anycombination thereof; a primary or secondary fatty amine derived from oneor more fatty acids selected from the group consisting of: corn oil,canola oil, coconut oil, safflower oil, sesame oil, palm oil, cottonseedoil, soybean oil, olive oil, sunflower oil, hemp oil, wheat germ oil,palm kernel oil, vegetable oil, tall oil, tallow oil, caprylic acid,capric acid, lauric acid, stearic acid, myristic acid, myristoleic acid,palmitic acid, palmitoleic acid, stearic acid, sapienic acid, elaidicacid, vaccenic acid, linoleic acid, arachidic acid, arachidonic acid,eicosapentaenoic acid, erucic acid, docosahexaenoic acid, behenic acid,lignoceric acid, cerotic acid, oleic acids (cis- and trans-), and anycombination thereof; and any combination thereof.
 11. The treatmentfluid of claim 10 wherein the at least one compound is a reactionproduct of a reaction between (i) an alkylating agent and (ii) a secondintermediate resulting from a reaction between a dialkylaminoalkylamineand a first intermediate, the first intermediate resulting from areaction between an acrylate or a methacrylate and an amine.
 12. Thetreatment fluid of claim 6 wherein the hydrate inhibitor furthercomprises a solvent selected from the group consisting of: an alcohol,methanol, ethanol, isopropyl alcohol, glycol, glycol ethers, an organicsolvent, toluene, xylene, monobutyl ether, hexane, cyclohexane, and anycombination thereof.
 13. The treatment fluid of claim 6 wherein X⁻ andY⁻ are selected from the group consisting of: a carboxylate, a halide, asulfate, an organic sulfonate, a phosphate, a phosphonate, a hydroxide,and any combination thereof.
 14. The treatment fluid of claim 6, whereinthe amine is selected from the group consisting of: a synthetic primaryor secondary amine selected from the group consisting of: butylamine,amine, hexylamine, octylamine, dodecylamine, N-methyldodecylamine,N-methyloctylamine, didodecylamine, and any combination thereof; aprimary or secondary fatty amine derived from one or more fatty acidsselected from the group consisting of: corn oil, canola oil, coconutoil, safflower oil, sesame oil, palm oil, cottonseed oil, soybean oil,olive oil, sunflower oil, hemp oil, wheat germ oil, palm kernel oil,vegetable oil, tall oil, tallow oil, caprylic acid, capric acid, lauricacid, stearic acid, myristic acid, myristoleic acid, palmitic acid,palmitoleic acid, stearic acid, sapienic acid, elaidic acid, vaccenicacid, linoleic acid, arachidic acid, arachidonic acid, eicosapentaenoicacid, erucic acid, docosahexaenoic acid, behenic acid, lignoceric acid,cerotic acid, oleic acids (cis- and trans-), and any combinationthereof; and any combination thereof.
 15. The treatment fluid of claim14 wherein the at least one compound is a reaction product of a reactionbetween (i) an alkylating agent and (ii) a second intermediate resultingfrom a reaction between a dialkylaminoalkylamine and a firstintermediate, the first intermediate resulting from a reaction betweenan acrylate or a methacrylate and an amine.
 16. The treatment fluid ofclaim 6 wherein the at least one compound is a reaction product of areaction between (i) an alkylating agent and (ii) a second intermediateresulting from a reaction between a dialkylaminoalkylamine and a firstintermediate, the first intermediate resulting from a reaction betweenan acrylate or a methacrylate and an amine.
 17. A hydrate inhibitorcomposition comprising: at least one compound of the structural formula:

wherein each of R¹, R², and R³ is independently a C₁ to C₆ hydrocarbonchain, wherein each of R⁴ and R⁵ is independently selected from thegroup consisting of hydrogen and any C₁ to C₅₀ hydrocarbon chainresulting from a reaction between an acrylate or a methacrylate and anamine, wherein R⁶ is selected from the group consisting of hydrogen anda C₁ to C₅₀ hydrocarbon chain, wherein X⁻ and Y⁻ are counter anionsselected from the group consisting of: a carboxylate, a halide, asulfate, an organic sulfonate, a phosphate, a phosphonate, a hydroxide,and any combination thereof, and wherein each of a and b isindependently an integer from 1 to 10; and a solvent selected from thegroup consisting of: an alcohol, methanol, ethanol, isopropyl alcohol,glycol, glycol ethers, an organic solvent, toluene, xylene, monobutylether, hexane, cyclohexane, and any combination thereof.
 18. The hydrateinhibitor composition of claim 17, wherein the amine is selected fromthe group consisting of: a synthetic primary or secondary amine selectedfrom the group consisting of: butylamine, amine, hexylamine, octylamine,dodecylamine, N-methyldodecylamine, N-methyloctylamine, didodecylamine,and any combination thereof; a primary or secondary fatty amine derivedfrom one or more fatty acids selected from the group consisting of: cornoil, canola oil, coconut oil, safflower oil, sesame oil, palm oil,cottonseed oil, soybean oil, olive oil, sunflower oil, hemp oil, wheatgerm oil, palm kernel oil, vegetable oil, tall oil, tallow oil, caprylicacid, capric acid, lauric acid, stearic acid, myristic acid, myristoleicacid, palmitic acid, palmitoleic acid, stearic acid, sapienic acid,elaidic acid, vaccenic acid, linoleic acid, arachidic acid, arachidonicacid, eicosapentaenoic acid, erucic acid, docosahexaenoic acid, behenicacid, lignoceric acid, cerotic acid, oleic acids (cis- and trans-), andany combination thereof; and any combination thereof.
 19. The hydrateinhibitor composition of claim 18 wherein the at least one compound is areaction product of a reaction between (i) an alkylating agent and (ii)a second intermediate resulting from a reaction between adialkylaminoalkylamine and a first intermediate, the first intermediateresulting from a reaction between an acrylate or a methacrylate and anamine.
 20. The hydrate inhibitor composition of claim 17 wherein the atleast one compound is a reaction product of a reaction between (i) analkylating agent and (ii) a second intermediate resulting from areaction between a dialkylaminoalkylamine and a first intermediate, thefirst intermediate resulting from a reaction between an acrylate or amethacrylate and an amine.